Y Intercept Hong Kong Ltd Has $1.60 Million Holdings in Ascendis Pharma A/S $ASND

Y Intercept Hong Kong Ltd grew its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 104.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,059 shares of the biotechnology company’s stock after buying an additional 4,108 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Ascendis Pharma A/S were worth $1,602,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Perceptive Advisors LLC bought a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $166,367,000. Adage Capital Partners GP L.L.C. raised its position in shares of Ascendis Pharma A/S by 40.4% in the second quarter. Adage Capital Partners GP L.L.C. now owns 459,606 shares of the biotechnology company’s stock valued at $79,328,000 after purchasing an additional 132,201 shares during the period. Marshall Wace LLP raised its holdings in Ascendis Pharma A/S by 425.5% in the 2nd quarter. Marshall Wace LLP now owns 117,162 shares of the biotechnology company’s stock valued at $20,222,000 after acquiring an additional 94,868 shares during the period. Braun Stacey Associates Inc. bought a new position in shares of Ascendis Pharma A/S during the third quarter worth approximately $18,678,000. Finally, Qube Research & Technologies Ltd increased its position in Ascendis Pharma A/S by 83.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock worth $34,700,000 after buying an additional 91,412 shares during the period.

Ascendis Pharma A/S Stock Up 1.0%

Shares of NASDAQ:ASND opened at $226.10 on Friday. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $242.00. The business’s 50 day moving average is $212.18 and its 200 day moving average is $201.32. The stock has a market cap of $14.01 billion, a price-to-earnings ratio of -50.92, a PEG ratio of 1.18 and a beta of 0.46.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The company had revenue of $250.71 million during the quarter, compared to the consensus estimate of $246.91 million. As a group, equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ASND shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Wolfe Research started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 price objective for the company. TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, January 7th. Barclays assumed coverage on Ascendis Pharma A/S in a report on Tuesday. They issued an “overweight” rating and a $342.00 price objective for the company. Finally, Bank of America boosted their price target on shares of Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $270.76.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.